Antimuscarinic medication use and risk of glaucoma in patients with overactive bladder: a literature review and disproportionality analysis using individual case safety reports from FAERS
Canadian Journal of Physiology and Pharmacology · 01.01.2026 · 104 · 1-8
DOI: 10.1139/cjpp-2025-0309 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Canadian Journal of Physiology and Pharmacology, erschienen am 01.01.2026. Verfasst von Hasti Sadeghi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Western University, London, ON, Canada. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Glaucoma, Muscarinic Antagonists. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study investigated the potential association between antimuscarinic medications and glaucoma by integrating evidence from a literature review with pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS). A systematic search of MEDLINE and EMBASE through 15 July 2025 identified eight studies, one pooled analysis of two randomized controlled trials, five observational studies, and two case reports that collectively suggested an association between anticholinergic use and increased risk of glaucoma or elevated intraocular pressure. Concurrently, an active-comparator restricted disproportionality analysis of FAERS data (2004Q1–2023Q4) was conducted to compare glaucoma reports among users of oxybutynin, tolterodine, solifenacin, darifenacin, fesoterodine, and trospium versus mirabegron. Adjusted reporting odds ratios (RORs) and information components (IC025) were calculated following READUS-PV guidelines. Compared with mirabegron, antimuscarinics demonstrated a higher reporting rate of glaucoma (adjusted ROR: 3.02; 95% CI: 2.03–4.50; IC025: 0.15), with tolterodine showing the strongest signal (adjusted ROR: 7.67; 95% CI: 4.90–12.02; IC025: 1.24), followed by darifenacin, fesoterodine, and solifenacin. No signals were observed for oxybutynin or trospium. These findings suggest that certain antimuscarinics, particularly tolterodine, darifenacin, and fesoterodine, may be associated with an increased risk of glaucoma and warrant further pharmacoepidemiologic investigation to confirm safety and inform prescribing decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, Western University, London, ON, Canada.
- Department of Physiology and Pharmacology, Western University, London, ON, Canada.
- ICES Western, London, ON, Canada.
- Department of Epidemiology & Biostatistics, Western University, London, ON, Canada.
- Healthy Active Living and Obesity Research Group, Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada.
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
ORCID-Profile: Flory T Muanda
Zitieren
APA
Sadeghi, H., Lau, R., Omrani, M., Ahmadi, F., Chalabianloo, N., Sampasa-Kanyinga, H., & Muanda, F. (2026). Antimuscarinic medication use and risk of glaucoma in patients with overactive bladder: a literature review and disproportionality analysis using individual case safety reports from FAERS. Canadian Journal of Physiology and Pharmacology, 104, 1-8. https://doi.org/10.1139/cjpp-2025-0309
Vancouver
Sadeghi H, Lau R, Omrani M, Ahmadi F, Chalabianloo N, Sampasa-Kanyinga H, et al. Antimuscarinic medication use and risk of glaucoma in patients with overactive bladder: a literature review and disproportionality analysis using individual case safety reports from FAERS. Canadian Journal of Physiology and Pharmacology. 2026;104:1-8. doi:10.1139/cjpp-2025-0309
BibTeX
@article{Sadeghi2026,
author = {Sadeghi, Hasti and Lau, Rinko and Omrani, Mohammad Ali and Ahmadi, Fatemeh and Chalabianloo, Niaz and Sampasa-Kanyinga, Hugues and Muanda, Flory T},
title = {Antimuscarinic medication use and risk of glaucoma in patients with overactive bladder: a literature review and disproportionality analysis using individual case safety reports from FAERS},
journal = {Canadian Journal of Physiology and Pharmacology},
year = {2026},
volume = {104},
pages = {1--8},
doi = {10.1139/cjpp-2025-0309}
}
EUVIMED